GeneDx Holdings Corp. (NASDAQ:WGS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• GeneDx Holdings Corp. has received a consensus rating of "Moderate Buy" from twelve brokerages, with an average target price of $112.80.
• Recent reports show that insider sales have occurred, with the Director Jason Ryan selling 38,072 shares and CEO Katherine Stueland selling 10,501 shares, resulting in significant decreases in their ownership stakes.
• In the first quarter, institutional investors such as GAMMA Investing LLC increased their holdings in GeneDx by over 151%, contributing to institutional ownership now at 61.72%.

Shares of GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $112.80.

Several analysts have recently issued reports on WGS shares. BTIG Research upped their price objective on GeneDx from $125.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday. Guggenheim reiterated a "buy" rating and set a $115.00 price target (up from $88.00) on shares of GeneDx in a research report on Monday, June 30th. Canaccord Genuity Group set a $155.00 price target on GeneDx and gave the stock a "buy" rating in a research note on Monday, October 20th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of GeneDx in a research note on Friday. Finally, Piper Sandler upped their price target on GeneDx from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday, September 11th.

Insider Buying and Selling

In other GeneDx news, Director Jason Ryan sold 38,072 shares of the business's stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total transaction of $4,846,565.60. Following the transaction, the director owned 103,284 shares in the company, valued at $13,148,053.20. The trade was a 26.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 10,501 shares of GeneDx stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $121.47, for a total value of $1,275,556.47. Following the transaction, the chief executive officer owned 14,578 shares in the company, valued at approximately $1,770,789.66. This trade represents a 41.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 556,371 shares of company stock worth $67,489,314. 29.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock worth $39,000 after purchasing an additional 264 shares during the period. US Bancorp DE grew its holdings in GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after buying an additional 548 shares in the last quarter. AlphaQuest LLC increased its position in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company's stock worth $70,000 after purchasing an additional 594 shares in the last quarter. KBC Group NV acquired a new stake in GeneDx in the 1st quarter valued at about $81,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of GeneDx during the 1st quarter worth $132,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Performance

NASDAQ:WGS opened at $128.87 on Friday. The firm has a market capitalization of $3.70 billion, a P/E ratio of 2,577.40 and a beta of 1.98. The company has a fifty day moving average of $123.22 and a 200-day moving average of $97.73. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. GeneDx has a twelve month low of $55.17 and a twelve month high of $136.00.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.40. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. The company had revenue of $102.69 million for the quarter, compared to analysts' expectations of $86.00 million. GeneDx has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that GeneDx will post 0.97 EPS for the current year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.